August 2007

Dear:

SORIATANE® (acitretin) Capsules are now only available with VersaFoam-EF™ in one convenient kit.

The NDC numbers for the **SORIATANE CK Convenience Kit™** are:
SORIATANE 10mg NDC 0145-3800-01
SORIATANE 25mg NDC 0145-4300-01

Wholesale Item Numbers for the **SORIATANE CK CONVENIENCE KIT** are:

Wholesaler	**Strength (mg)**	**Item number**
ABC		
Bergen	10	609949
	25	609964
Amerisource	10	5011341
	25	5011358
Cardinal	10	4001640
	25	4001657
McKesson	10	1344977
	25	1347087

Beginning September 10, 2007, SORIATANE Capsules are only available in the SORIATANE CK CONVENIENCE KIT.

About VERSAFOAM-EF:

- Cosmetic formulation foam that provides the moisturizing qualities of a fine skincare product
  - Disappears into the skin with gentle rubbing
  - Makes the skin feel silky and smooth

About SORIATANE:

- The only oral systemic treatment approved for both initial and maintenance psoriasis therapy
- Proven efficacy in 5 types of severe psoriasis[1]
- Flexible dosing: available in 10 mg or 25 mg capsules in the SORIATANE CK CONVENIENCE KIT
- Has not been shown to be immunosuppressive[2]
- Has experience in over 1 million patients worldwide*

Please see accompanying full Prescribing Information, including boxed CONTRAINDICATIONS and WARNINGS

Stiefel Laboratories is committed to bringing quality and value to the patients who use our products. Please contact us at 888-500-DERM with any questions.

Given its efficacy, well-documented safety profile, and flexibility of dosing, you can see why SORIATANE may be a treatment option for your adult patients suffering with severe psoriasis. For more information about SORIATANE, please contact your Stiefel sales representative or call **1-888-STIEFEL.**

SORIATANE is indicated for the treatment of severe psoriasis in adults. Due to the risk of severe birth defects, in females of reproductive potential, SORIATANE should be reserved for nonpregnant patients with severe psoriasis who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments.

CONTRAINDICATIONS AND WARNINGS: SORIATANE® (acitretin) must not be used by females who are pregnant or who may become pregnant during therapy or at any time for at least 3 years after discontinuation of treatment. SORIATANE also must not be used by females of reproductive potential who may not use 2 effective forms of contraception (birth control) simultaneously, for at least 1 month before, during and for at least 3 years after treatment. Two effective forms of contraception (birth control) are to be used simultaneously, even when 1 form is a hormonal contraceptive. Patients should not self medicate with St. John's Wort because of possible interaction with hormonal contraceptives. Prescribers must obtain negative results for 2 pregnancy tests before initiating treatment with SORIATANE. The first test is a screening test; the second is a confirmation test done during the first 5 days of the menstrual period immediately preceding SORIATANE therapy. For patients with amenorrhea, the second test should be done at least 11 days after the last act of unprotected sexual intercourse. Timing of pregnancy testing throughout the treatment course should be monthly or individualized based on the prescriber's clinical judgment. Females must sign a Patient Information/Consent about the risks of birth defects. SORIATANE is a metabolite of etretinate and major fetal abnormalities have been reported with both drugs. SORIATANE can interact with ethanol to form etretinate. Therefore, females of reproductive potential must not ingest ethanol during treatment and for 2 months after cessation of treatment. Before prescribing, please see complete pregnancy warning in the accompanying complete product information. Females who have undergone treatment with Tegison® (etretinate) must continue to follow the contraception requirements for Tegison.

Common side effects include: cheilitis, rhinitis, dry mouth, arthralgia, spinal hyperostosis, alopecia, skin peeling, dry skin, nail disorder, pruritus, erythematous rash, hyperesthesia, paresthesia, paronychia, skin atrophy, sticky skin, and alteration in lipids.

Less frequent, but potentially serious, adverse events include hepatotoxicity, pancreatitis, and pseudotumor cerebri, as well as hyperostosis, alteration in lipids with possible cardiovascular effects, and ophthalmologic effects

Sincerely,
[Insert E-Signature]
[Insert Name]
Product Manager, SORIATANE

*IMS Health Rx Data. August 2007.

References: 1. Data on file . Stiefel Laboratories, Inc. **2.** Lebwohl N, Menter A, Koo J, Feldman SR. Case studies in severe psoriasis: a clinical strategy. *J Dermatolog Treat.* 2003;14(suppl 2):26-46.

Stiefel Laboratories, Inc.
Corporate Headquarters
255 Alhambra Circle,
Coral Gables, FL 33134
Tel 305-443-3800 • Fax 305-443-3467
www.stiefel.com

Stiefel Laboratories, Inc.
US Sales and Marketing
6340 Sugarloaf Parkway, Suite 400,
Duluth, GA 30097
Tel 770-945-0101 • Fax 770-945-5424